Active and latent tuberculosis in patients with systemic lupus erythematosus living in the United States

Journal of Clinical Rheumatology

Volumn 15, Issue 5, 2009, Pages 226-229

  Chu, Alvina D ^a   Polesky, Andrea H ^b   Bhatia, Gulshan ^b   Bush, Thomas M ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Immunosuppressed; Infection; Systemic lupus erythematosus; Tuberculosis

Indexed keywords

ISONIAZID; PREDNISONE; RIFAMPICIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMMUNITY HOSPITAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

ADULT; CALIFORNIA; EMIGRANTS AND IMMIGRANTS; FEMALE; HOSPITALS, COUNTY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS;

EID: 69549088524     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181b0c85d     Document Type: Article

References (36)

1. Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am. 2001;15:335-361. (Pubitemid 32606903)
2. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19-26. (Pubitemid 43235123)
3. Pope JE, Krizova A, Ouimet JM, et al. Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case-control study of patients with SLE or noninflammatory musculoskeletal disorders. J Rheumatol. 2004;31:274-279. (Pubitemid 38160748)
4. Mok MY, Wong SS, Chan TM, et al. Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:280-284. (Pubitemid 46189789)
5. Kim HA, You CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998;16:9-13. (Pubitemid 28133475)
6. Phan JC, Bush TM, Donald F, et al. Clinical and laboratory features of patients of Vietnamese descent with systemic lupus erythematosus. Lupus. 1999;8:521-524. (Pubitemid 29452564)
7. Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving Tuberculosis Elimination. Am J Respir Crit Care Med. 2007;175:75-79.
8. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol. 2002;16:281-291. (Pubitemid 36526644)
9. Gilliland WR, Tsokos GC. Prophylactic use of antibiotics and immunizations in patients with SLE. Ann Rheum Dis. 2002;61:191-192. (Pubitemid 34177744)
10. Andonopoulos AP, Safridi C, Karokis D, et al. Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids? Clin Rheumatol. 1998;17:181-185. (Pubitemid 28346364)
11. Gaitonde S, Pathan E, Sule A, et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis. 2002;61:251-253. (Pubitemid 34177757)
12. Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor (alpha). Ann Rheum Dis. 2005;64(suppl 4):29-30.
13. Winthrop KL, Siegel JN, Jereb J, et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum. 2005;52:2968-2974. (Pubitemid 41447075)
14. Ermann J, Bermas BL. The biology behind the new therapies for SLE. Int J Clin Pract. 2007;61:2113-2119.
15. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biologic agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66(suppl 3):iii2-iii22.
16. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
17. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am Respir Crit Care Med. 2000;161(4 pt 2):S221-S247.
18. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-850.
19. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54(RR-12):1-81.
20. CDC. Reported Tuberculosis in the United States, 2006. Atlanta, GA: US Department of Health and Human Services, CDC; 2007.
21. Rovensky J, Kovalancik M, Kristufek P, et al. Contribution to the problem of occurrence of tuberculosis in patients with systemic lupus erythematosus. Z Rheumatol. 1996;55:180-187. (Pubitemid 26290777)
22. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Rosales S, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases: a case-series. Clin Exp Rheumatol. 1999;17:289-296. (Pubitemid 29265675)
23. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, et al. High risk of tuberculosis in systemic lupus erythematosus? Lupus. 2006;15:232-235.
24. Sayarlioglu M, Inanc M, Kamali S, et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extra pulmonary localization. Lupus. 2004;13:274-278. (Pubitemid 38649628)
25. Purice S, Mitu S, Popescu T, et al. The relationship between systemic lupus erythematosus and tuberculosis. Med Interne. 1982;20:191-196. (Pubitemid 13204881)
26. Balakrishnan C, Mangat G, Mittal G, et al. Tuberculosis in patients with systemic lupus erythematosus. J Assoc Physicians India. 1998;46:682-683. (Pubitemid 128524058)
27. Shyam C, Malaviya AN. Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. Rheumatol Int. 1996;16:1-3. (Pubitemid 126437686)
28. Victorio-Navarra ST, Dy EE, Arroyo CG, et al. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum. 1996;26:628-634. (Pubitemid 27024199)
29. Tam LS, Li EK, Wong SM, et al. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296-300. (Pubitemid 35252543)
30. Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002;20:127-132. (Pubitemid 34413690)
31. Feng PH, Tan TH. Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis. 1982;41:11-14.
32. Hou CL, Tsai YC, Chen LC, et al. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared. Clin Rheumatol. 2008;27:557-563.
33. Chadha VK. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis. 2005;9:1072-1082.
34. Tuberculosis Records. Santa Clara, CA: Public Health Department, Epidemiology and Data Management; 2005.
35. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation form a public health tuberculosis clinic. Chest. 2005;128:116-123. (Pubitemid 40994462)
36. Passel J, Cohn D. Immigration to Play Lead Role in Future US Growth. US Population Projection: 2005-2050. Washington, DC: Pew Research Publications; 2008.